Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-04-04

Clinical Trial Update: A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance [Phase 2]

View source ↗

Summary

Phase 2 study assessing ETC-1002 (bempedoic acid) for efficacy and safety in individuals with statin intolerance; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ETC-1002 (bempedoic acid)

Snippet

Sponsor: Esperion Therapeutics, Inc. | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED | Results posted: 2022-04-04